

**May 30, 2019**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

**Subject: Submission of half yearly disclosure on Related Party Transactions**

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure on Related Party Transaction, on consolidated basis, for the half year ended March 31, 2019 drawn in accordance with applicable accounting standards.

You are requested to take the same on record.

Thanking you,

Yours faithfully,  
**For Sequent Scientific Limited**



**Krupesh Mehta**  
Company Secretary

**Encl: A/a**

**SeQuent Scientific Limited**

**Disclosure of related party transactions on consolidated basis**

*In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018*

**A List of related parties****a) Key management personnel**

Mr. Manish Gupta, Chief Executive Officer & Managing Director  
Mr. Sharat Narasapur, Joint Managing Director  
Mr. Tushar Mistry, Chief Financial Officer  
Mr. Krupesh Mehta, Company Secretary  
Dr. Huyesin Aydin, Non-Executive Director, Alivira Animal Health Limited, India  
Mr. K E C Rajakumar, Non-Executive Director  
Dr. S Devendra, Non-Executive Director  
Dr. Gopakumar G. Nair, Chairman and Independent Director  
Dr. Kausalya Santhanam, Independent Director  
Mr. Narendra Mairpady, Independent Director

**b) Enterprises owned or significantly influenced by individuals who have control/significant influence over the Company/ subsidiaries**

Strides Pharma Sciences Limited (formerly known as Strides Shasun Limited)  
Atma Projects  
Agnus Holdings Private Limited  
Chayadeep Properties Private Limited  
Pronomz Ventures LLP  
Fitch Participacoes Ltda  
Solara Active Pharma Sciences Limited (From 01 October 2017)  
SeQuent Penems Private Limited (From 01 October 2017)



## Disclosure of related party transactions on consolidated basis

## B Transactions during the period 01 October 2018 to 31 March 2019

(Amount are in INR Million)

| Particulars                              | Key management personnel | Enterprises owned or significantly influenced by individuals who have control/ significant influence over the Company / subsidiaries |
|--|--------------------------|--|
| <b>Sale of materials/services</b>        |                          |  |
| Strides Pharma Sciences Limited          |                          | 0.50   |
| Solara Active Pharma Sciences Limited    |                          | 95.48  |
| <b>Interest expense</b>                  |                          |  |
| Fitch Participacoes Ltda                 |                          | 5.43   |
| Dr.Huyesin Aydin                         | 2.83                     |  |
| <b>Purchase of materials</b>             |                          |  |
| Solara Active Pharma Sciences Limited    |                          | 46.56  |
| Strides Pharma Sciences Limited          |                          | 0.79   |
| <b>Managerial remuneration</b>           |                          |  |
| Mr. Manish Gupta                         | 30.48                    |  |
| Mr. Sharat Narsapur                      | 3.74                     |  |
| Mr. Tushar Mistry                        | 3.44                     |  |
| Mr. Krupesh Mehta                        | 0.80                     |  |
| Directors Sitting Fees                   | 0.67                     |  |
| <b>Reimbursement of expenses from</b>    |                          |  |
| Solara Active Pharma Sciences Limited    |                          | 1.02   |
| <b>Rent expense</b>                      |                          |  |
| Solara Active Pharma Sciences Limited    |                          | 4.20   |
| Sequent Penems Pvt Ltd                   |                          | 0.90   |
| <b>Security deposit given to</b>         |                          |  |
| Solara Active Pharma Sciences Limited    |                          | 4.20   |
| <b>Loans/advances repaid by Group</b>    |                          |  |
| Fitch Participacoes Ltda                 |                          | 2.06   |
| <b>Loans/advances taken by the Group</b> |                          |  |
| Dr.Huyesin Aydin                         | 11.89                    |  |

## C Balance as at 31 March 2019

(Amount are in INR Million)

|   |        |       |
|---|--------|-------|
| <b>Trade Receivables / other current assets</b> |        |       |
| Strides Pharma Sciences Limited                 |        | 0.52  |
| Naari Pharma Private Limited                    |        | 8.93  |
| Solara Active Pharma Sciences Limited           |        | 81.89 |
| <b>Security deposit receivable</b>              |        |       |
| Solara Active Pharma Sciences Limited           |        | 4.20  |
| SeQuent Penems Pvt Ltd                          |        | 2.50  |
| <b>Trade payables</b>                           |        |       |
| Atma Projects                                   |        | 0.20  |
| Strides Pharma Sciences Limited                 |        | 7.94  |
| Solara Active Pharma Sciences Limited           |        | 51.75 |
| SeQuent Penems Pvt Ltd                          |        | 1.94  |
| <b>Loan payable</b>                             |        |       |
| Fitch Participacoes Ltda                        |        | 72.70 |
| Dr.Huyesin Aydin                                | 152.84 |       |

For Sequent Scientific Limited

  
Tushar Mistry  
Chief Financial Officer

  
Krupesh Mehta  
Company Secretary

